UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File Number: 001-41324
AKANDA CORP.
(Name of registrant)
1a, 1b Learoyd Road
New Romney TN28 8XU, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F | ☐ Form 40-F |
EXHIBIT INDEX
On February 20, 2024, Akanda Corp. issued a press release entitled “Akanda Corp. Provides Further Update on Annual Meeting of its Shareholders”, a copy of which is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.
The press release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.
Exhibit No. |
Description | |
99.1 | Press Release Issued by Akanda Corp. to Provide Further Update on Annual Meeting of its Shareholders |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AKANDA CORP. | |||
(Registrant) | |||
Date: February 20, 2024 | By: | /s/ Katie Field | |
Name: | Katie Field | ||
Title: | Interim Chief Executive Officer and Director |
2
Exhibit 99.1
Akanda Corp. Provides Further Update on Annual Meeting of its Shareholders
London, February 20, 2024 – Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN), an international medical cannabis company, today announces that it has received an order from the Ontario Superior Court of Justice (the “Court”) permitting Akanda to hold its annual meeting of shareholders (the “Meeting”) on or before March 23, 2024, pursuant to an application to the Court previously announced by the Company on February 20, 2024. Prior to the order from the Court, the Company would have had to hold the Meeting on or before February 22, 2024.
About Akanda Corp.
Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer and distributor with an EU GMP certified indoor grow facility; CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships with California-based Cookies, the most globally recognized cannabis company in the world; Cansativa Group, a leading importer and distributor of medical cannabis in Europe; and Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK.
Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram
Investor Contact
ir@akandacorp.com
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company’s securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.